Stay up to date on all things ATS 2026 International Conference. Check out latest news, key deadlines, and exciting program updates below. Don’t miss a beat… and see you in Orlando, May 15-20, 2026!
-
Opening Ceremony Keynote Examines the “Giant Leap” of AI and the Future of Health Care
Robert Wachter, MD, has been a celebrated and influential leader in health care for decades. He released his latest book, A Giant Leap: How AI Is Transforming Healthcare and What That Means for Our Future, on Feb. 3. Dr. Wachter will deliver a can’t-miss keynote lecture, “How AI is Transforming Health Care,” at the ATS 2026 International Conference Opening Ceremony, 4:15–5:30 p.m. ET on Saturday, May 16.
-
How a Harrowing Medical Journey Led Plenary Speaker to Reconceive Patient Care
Rana L. Awdish, MD, MS, was navigating the end of her critical care fellowship when a serious medical event left her clinically dead before she was eventually resuscitated. This life-altering experience as a patient led Dr. Awdish to several epiphanies about the physician-patient relationship paradigm and the critical role of communication in care. Dr. Awdish will be the keynote speaker at this year’s Plenary Session at the ATS 2026 International Conference, 11:45 a.m.–1 p.m. ET on Tuesday, May 19.
-
Public Advisory Roundtable Celebrates 25 Years at ATS 2026 Orlando
The American Thoracic Society Public Advisory Roundtable celebrates 25 years in May 2026 with a series of discussions and special events at the ATS 2026 International Conference aimed to bolster its goal of bringing patient perspectives to the Society’s deliberations, policies, and activities. This year also marks 20 years of hosting the Patients & Experts Forum. The free event starts at 10 a.m. ET, Saturday, May 16, with the panel session, “Drug Repurposing and Complementary Therapies for Lung Health."
-
International Participants Center Offers Dynamic Global Programming and Networking
The International Participants Center (IPC) at the ATS 2026 International Conference will present a robust series of 12 multidisciplinary talks and gatherings open to all conference participants, May 16-19, during ATS 2026 Orlando. The IPC will also host kiosks representing more than a dozen international organizations and societies with representatives available for networking and conversations about global health.
-
New Vaccine Adoption Strategies from Multi-Year Grant Initiative to be Shared at ATS 2026 Orlando
The ATS is one of seven specialty societies awarded a grant by the Council of Medical Specialty Societies and CDC to increase COVID-19, influenza, and routine vaccination rates among high-risk adult patients in the United States. Data collection for this initiative wrapped in summer 2025, and the ATS is now using its findings to build a new toolkit to help health systems improve adult vaccination rates.
-
ATS Assembly Meetings to Connect Members in Orlando
The 14 assemblies within the ATS will hold membership meetings at the International Conference inside Orlando’s Orange County Convention Center from 5–7 p.m. ET on Sunday and Monday, May 17-18.
-
Make the Most of Your Free Time for a Magical Orlando Experience
Orlando is a unique city in the Sunshine State, with world-famous theme parks, resorts, and gorgeous natural scenery. Before arriving at ATS 2026 Orlando this May, start planning to make the most of your free time!
-
Let Camp ATS Make the International Conference a Family Affair in Orlando
Camp ATS has the kids covered while parents attend education sessions and network at ATS 2026 Orlando. The program offers a fun, safe, and engaging experience designed just for kids aged six months to 12 years, allowing adults to enjoy the International Conference worry-free.
-
A Landmark Moment: A Discussion on JASCAYD® (nerandomilast) tablets
Please join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium. Click Here to learn more.
-
ATS 2026 Orlando Program Aims to Maintain Momentum from Recent Breakthroughs in ILD and IPF
The ATS 2026 International Conference will spotlight a wide range of recent investigative and clinical advances in the treatment of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), including the development of nerandomilast, the first FDA-approved therapy for IPF in over a decade. Susan K. Mathai, MD, spoke with ATS Conference News to preview several conference program highlights related to ILD and IPF.